Drug Price Transparency Act

Summary

Drug Price Transparency Act This bill requires certain manufacturers of drugs that are covered under Medicare medical services to report pricing information to the Centers for Medicare & Medicaid Services. Specifically, manufacturers of such drugs that do not have rebate agreements under the Medicaid Drug Rebate Program must report similar information as is required under the program, including average sales price, total units, and wholesale acquisition cost. Manufacturers that fail to comply or that report false information are subject to civil penalties.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 4 April 2019

   Introduced

   Introduced in House

   Source: IntroReferral

2. 4 April 2019

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

3. 4 April 2019

   Introduced

   Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

   Source: IntroReferral

4. 4 April 2019

   Introduced

   Introduced in House

   Source: IntroReferral

5. 5 April 2019

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

6. 21 May 2019

   Committee

   Subcommittee Hearings Held.

   Source: Committee

Votes

No vote records are attached yet.

Versions

• Introduced in House · 4 April 2019 · Download file

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 4 April 2019

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 4 April 2019

  ViewDownloadOpen at official source

  Leesvertaling

  Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

  Vertaal naarNL · DutchDE · GermanFR · FrenchES · SpanishIT · ItalianPL · PolishPT · PortugueseSV · SwedishDA · DanishFI · FinnishEL · GreekCS · CzechHU · HungarianRO · RomanianBG · BulgarianHR · CroatianSK · SlovakSL · SlovenianLT · LithuanianLV · LatvianET · EstonianGA · IrishMT · Maltese

  Vertaal document

  Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

• Introduced in House

  summary · EN · 4 April 2019

  Open at official source

  Leesvertaling

  Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

  Vertaal naarNL · DutchDE · GermanFR · FrenchES · SpanishIT · ItalianPL · PolishPT · PortugueseSV · SwedishDA · DanishFI · FinnishEL · GreekCS · CzechHU · HungarianRO · RomanianBG · BulgarianHR · CroatianSK · SlovakSL · SlovenianLT · LithuanianLV · LatvianET · EstonianGA · IrishMT · Maltese

  Vertaal document

  Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

• Rep. Doggett, Lloyd [D-TX-37] · D · Sponsor
• Rep. Buchanan, Vern [R-FL-16] · R · Sponsor
• · hsif00 · Standing
• · hswm00 · Standing

Related records

• related to → Lower Costs, More Cures Act of 2019
• related to → Removing Barriers to Colorectal Cancer Screening Act of 2020
• related to ← Prescription Drug STAR Act
• related to ← More Efficient Tools to Realize Information for Consumers Act
• related to ← Strengthening Average Sales Price Reporting Act of 2019
• related to ← Lower Costs, More Cures Act of 2019